A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
30actual
Sites
4
Countries
Hungary, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-23 | actual | When the study began enrolling |
| Primary completion | 2026-07-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-13 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Liver Dysfunction
- Healthy
Intervention
- Drug: Lepodisiran — also filed as LY3819469
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Lepodisiran
measured Baseline Up to 9 weeks
PK: Maximum Concentration (Cmax) of Lepodisiran
measured Baseline Up to 9 weeks
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed